Effect of duplicate isolates of methicillin-susceptible and methicillin-resistant Staphylococcus aureus on antibiogram data

被引:22
作者
Horvat, RT
Klutman, NE
Lacy, MK
Grauer, D
Wilson, M
机构
[1] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA
[2] Ortho McNeil Pharmaceut, Clin Commun, Kansas City, KS 66160 USA
[3] Univ Kansas, Sch Pharm, Kansas City, KS 66160 USA
[4] Univ Kansas, Med Ctr Hosp, Clin Labs, Kansas City, KS 66160 USA
关键词
D O I
10.1128/JCM.41.10.4611-4616.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Duplicate Staphylococcus aureus isolates were analyzed to determine the impact of multiple isolates from the same patient on annual antibiogram data. During a 6-year period (1996 to 2001), 3,227 patients with 4,844 S. aureus isolates were evaluated. A total of 39% of patients with methicillin-resistant S. aureus (MRSA) (n = 860) and 23% of patients with methicillin-susceptible S. aureus (MSSA) (n = 2,367) infections had duplicate isolates. Cumulative data show that 91% of the patients during this 6-year period with duplicate isolates (2 to 13 duplicates/year) did not switch between MSSA and MRSA but retained the original S. aureus strain whether it was MSSA or MRSA. Rates of MRSA were calculated for each year by using all isolates and then eliminating duplicates. The impact of duplicate MRSA and MSSA isolates was evaluated by using the ratio of isolates per patient such that ratios of >1.0 indicate >1 isolate per patient. The 6-year ratio for MRSA was 1.90 isolates/patient, and the ratio for MSSA was 1.35. A significant difference (P < 0.05) was noted in the MRSA rates in 4 of 6 years when duplicate isolates were removed. Common phenotypic antibiogram patterns were compared for all MRSA isolates during the 6-year period, and 64% were of a single antibiogram phenotype. Eighty-eight percent of patients with duplicate MRSA isolates had phenotypically identical multiple isolates. The rate of MRSA differs when duplicate isolates are removed from the antibiogram data.
引用
收藏
页码:4611 / 4616
页数:6
相关论文
共 22 条
  • [1] Nosocomial methicillin-resistant and methicillin-susceptible, Staphylococcus aureus primary bacteremia:: At what costs
    Abramson, MA
    Sexton, DJ
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (06) : 408 - 411
  • [2] Spread of methicillin-resistant Staphylococcus aureus in a neonatal intensive unit associated with understaffing, overcrowding and mixing of patients
    Andersen, BM
    Lindemann, R
    Bergh, K
    Nesheim, BI
    Syversen, G
    Solheim, N
    Laugerud, F
    [J]. JOURNAL OF HOSPITAL INFECTION, 2002, 50 (01) : 18 - 24
  • [3] Resistance mechanisms of Gram-positive bacteria
    Berger-Bächi, B
    [J]. INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2002, 292 (01) : 27 - 35
  • [4] Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus
    Blot, SI
    Vandewoude, KH
    Hoste, EA
    Colardyn, FA
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (19) : 2229 - 2235
  • [5] Antimicrobial resistance in intensive care units
    Fridkin, SK
    Gaynes, RP
    [J]. CLINICS IN CHEST MEDICINE, 1999, 20 (02) : 303 - +
  • [6] Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit
    Haddadin, AS
    Fappiano, SA
    Lipsett, PA
    [J]. POSTGRADUATE MEDICAL JOURNAL, 2002, 78 (921) : 385 - 392
  • [7] Prospective study of 424 cases of Staphylococcus aureus bacteraemia:: determination of factors affecting incidence and mortality
    Hill, PC
    Birch, M
    Chambers, S
    Drinkovic, D
    Ellis-Pegler, RB
    Everts, R
    Murdoch, D
    Pottumarthy, S
    Roberts, SA
    Swager, C
    Taylor, SL
    Thomas, MG
    Wong, CG
    Morris, AJ
    [J]. INTERNAL MEDICINE JOURNAL, 2001, 31 (02) : 97 - 103
  • [8] Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study)
    Jarlier, V
    Fosse, T
    Philippon, A
    [J]. INTENSIVE CARE MEDICINE, 1996, 22 (10) : 1057 - 1065
  • [9] Lamp K, 1996, Pharm Pract Manag Q, V16, P52
  • [10] Livermore DM, 2000, INT J ANTIMICROB AG, V16, pS3